{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:25:57Z","timestamp":1782253557788,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biophysical Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bpc.2022.106915","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T19:15:00Z","timestamp":1666898100000},"page":"106915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A theoretical study on binding and stabilization of galactose and novel galactose analogues to the human \u03b1-galactosidase A variant causing Fabry disease"],"prefix":"10.1016","volume":"292","author":[{"given":"Methus","family":"Klaewkla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jittithorn","family":"Prousoontorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanapon","family":"Charoenwongpaiboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpc.2022.106915_bb0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant \u03b1-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.bpc.2022.106915_bb0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/humu.10212","article-title":"Human gene mutation database (HGMD\u00ae): 2003 update","volume":"21","author":"Stenson","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bpc.2022.106915_bb0015","series-title":"Fabry disease: \u03b1-galactosidase A deficiency. Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease","first-page":"575","author":"Desnick","year":"2020"},{"key":"10.1016\/j.bpc.2022.106915_bb0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cca.2018.02.021","article-title":"Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ","volume":"481","author":"Ferri","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bpc.2022.106915_bb0025","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","article-title":"Catalytic mechanism of human \u03b1-galactosidase 2","volume":"285","author":"Guce","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bpc.2022.106915_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.1380030204","article-title":"Molecular basis of Fabry disease: mutations and polymorphisms in the human \u03b1-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bpc.2022.106915_bb0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.bpc.2022.106915_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2007.00198.x","article-title":"Structure\u2013function relationships in \u03b1-galactosidase a","volume":"96","author":"Garman","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.bpc.2022.106915_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1096-7192(02)00151-8","article-title":"Structural basis of Fabry disease","volume":"77","author":"Garman","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bpc.2022.106915_bb0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human \u03b1-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bpc.2022.106915_bb0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of \u03b1-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bpc.2022.106915_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bpc.2022.106915_bb0065","doi-asserted-by":"crossref","first-page":"10042","DOI":"10.1074\/jbc.RA118.001774","article-title":"Nicotiana benthamiana \u03b1-galactosidase A1. 1 can functionally complement human \u03b1-galactosidase A deficiency associated with Fabry disease","volume":"293","author":"Kytidou","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bpc.2022.106915_bb0070","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fpls.2017.01026","article-title":"Human alpha galactosidases transiently produced in nicotiana benthamiana leaves: new insights in substrate specificities with relevance for Fabry disease","volume":"8","author":"Kytidou","year":"2017","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.bpc.2022.106915_bb0075","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/prot.20922","article-title":"A simple clustering algorithm can be accurate enough for use in calculations of pKs in macromolecules","volume":"63","author":"Myers","year":"2006","journal-title":"Proteins Struct. Funct. Bioinformat."},{"key":"10.1016\/j.bpc.2022.106915_bb0080","doi-asserted-by":"crossref","first-page":"9233","DOI":"10.1039\/C9SC03342D","article-title":"\u03b1-d-Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabilizes therapeutic lysosomal \u03b1-galactosidase A in Fabry disease","volume":"10","author":"Artola","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bpc.2022.106915_bb0085","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bpc.2022.106915_bb0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metabol. Dis."},{"key":"10.1016\/j.bpc.2022.106915_bb0095","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The molecular basis of pharmacological chaperoning in human \u03b1-galactosidase","volume":"18","author":"Guce","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bpc.2022.106915_bb0100","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10545-011-9424-3","article-title":"Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease","volume":"35","author":"Porto","year":"2012","journal-title":"J. Inherit. Metabol. Dis."},{"key":"10.1016\/j.bpc.2022.106915_bb0105","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bpc.2022.106915_bb0110","doi-asserted-by":"crossref","first-page":"W537","DOI":"10.1093\/nar\/gks375","article-title":"H++ 3.0: automating p K prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations","volume":"40","author":"Anandakrishnan","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bpc.2022.106915_bb0115","doi-asserted-by":"crossref","first-page":"W368","DOI":"10.1093\/nar\/gki464","article-title":"H++: a server for estimating p Ka s and adding missing hydrogens to macromolecules","volume":"33","author":"Gordon","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bpc.2022.106915_bb0120","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/prot.20922","article-title":"A simple clustering algorithm can be accurate enough for use in calculations of pKs in macromolecules","volume":"63","author":"Myers","year":"2006","journal-title":"Proteins Struct. Funct. Bioinformat."},{"key":"10.1016\/j.bpc.2022.106915_bb0125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases \u03b1-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.bpc.2022.106915_bb0130","first-page":"S162","article-title":"Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective","volume":"30","author":"Guex","year":"2009","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bpc.2022.106915_bb0135","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling","volume":"18","author":"Guex","year":"1997","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bpc.2022.106915_bb0140","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bpc.2022.106915_bb0145","doi-asserted-by":"crossref","first-page":"8345","DOI":"10.1063\/1.465608","article-title":"The effect of long-range electrostatic interactions in simulations of macromolecular crystals: a comparison of the Ewald and truncated list methods","volume":"99","author":"York","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bpc.2022.106915_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10060879","article-title":"Fisetin inhibits osteogenic differentiation of mesenchymal stem cells via the inhibition of YAP","volume":"10","author":"Lorthongpanich","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.bpc.2022.106915_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/biom9100545","article-title":"Enhanced solubility and anticancer potential of Mansonone G by \u03b2-cyclodextrin-based host-guest complexation: a computational and experimental study","volume":"9","author":"Mahalapbutr","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bpc.2022.106915_bb0160","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cplett.2003.10.013","article-title":"Self-guided Langevin dynamics simulation method","volume":"381","author":"Wu","year":"2003","journal-title":"Chem. Phys. Lett."},{"key":"10.1016\/j.bpc.2022.106915_bb0165","series-title":"Advances in Protein Chemistry and Structural Biology","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/bs.apcsb.2018.10.009","article-title":"Chapter nine - Computational and modeling approaches to understand the impact of the Fabry\u2019s disease causing mutation (D92Y) on the interaction with pharmacological chaperone 1-deoxygalactonojirimycin (DGJ)","author":"Thirumal Kumar","year":"2019"},{"key":"10.1016\/j.bpc.2022.106915_bb0170","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bpc.2022.106915_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.116537","article-title":"Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists","volume":"335","author":"Klaewkla","year":"2021","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.bpc.2022.106915_bb0180","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.Py: an efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.bpc.2022.106915_bb0185","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.bpc.2022.106915_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2022.118790","article-title":"Unraveling the effect of A143T, P205T and D244N mutations in \u03b1-galactosidase A on its catalytic activity and susceptibility to globotriaosylceramide and iminosugar 1-deoxygalactonojirimycin chaperone","volume":"353","author":"Mahalapbutr","year":"2022","journal-title":"J. Mol. Liq."}],"container-title":["Biophysical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301462222001570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301462222001570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T07:58:21Z","timestamp":1759564701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301462222001570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":38,"alternative-id":["S0301462222001570"],"URL":"https:\/\/doi.org\/10.1016\/j.bpc.2022.106915","relation":{},"ISSN":["0301-4622"],"issn-type":[{"value":"0301-4622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A theoretical study on binding and stabilization of galactose and novel galactose analogues to the human \u03b1-galactosidase A variant causing Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Biophysical Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpc.2022.106915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106915"}}